Study of Mantle Cell Lymphoma Treatment by RiBVD (RIBVD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01457144
Recruitment Status : Completed
First Posted : October 21, 2011
Last Update Posted : March 16, 2016
Lymphoma Study Association
Janssen-Cilag Ltd.
Mundipharma Pte Ltd.
Roche Pharma AG
Chugai Pharma Europe Ltd.
Information provided by (Responsible Party):
French Innovative Leukemia Organisation

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : September 2014
  Actual Study Completion Date : March 2016